Iterum Therapeutics (NASDAQ:ITRM) Lowered to Sell Rating by Wall Street Zen

Iterum Therapeutics (NASDAQ:ITRM) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Iterum Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.00.

Iterum Therapeutics Price Performance

Shares of NASDAQ:ITRM opened at $0.60 on Friday. The company has a market cap of $29.07 million, a P/E ratio of -0.71 and a beta of 3.09. Iterum Therapeutics has a 1 year low of $0.57 and a 1 year high of $3.02. The stock’s fifty day moving average price is $0.69 and its 200-day moving average price is $0.85.

Iterum Therapeutics (NASDAQ:ITRM) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03). On average, sell-side analysts anticipate that Iterum Therapeutics will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On Iterum Therapeutics

An institutional investor recently bought a new position in Iterum Therapeutics stock. OneDigital Investment Advisors LLC bought a new position in Iterum Therapeutics PLC (NASDAQ:ITRM) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 101,000 shares of the company’s stock, valued at approximately $124,000. OneDigital Investment Advisors LLC owned 0.29% of Iterum Therapeutics as of its most recent filing with the SEC. Institutional investors own 9.21% of the company’s stock.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.